Chapters

Transcript

Video

What glucocorticoid dosing and/or biomarker metrics, such as 17-hydroxyprogesterone, might you consider when assessing suitability for CRF receptor antagonism with crinecerfont in the setting of CAH?

What glucocorticoid dosing and/or biomarker metrics, such as 17-hydroxyprogesterone, might you consider when assessing suitability for CRF receptor antagonism with crinecerfont in the setting of CAH?


Created by

CMEducation Resources | iQ&A Congenital Adrenal Hyperplasia (CAH) Medical Intelligence Zone 

Presenter

Perrin White, MD

Perrin White, MD

Chief, Division of Pediatric Endocrinology
Audre Newman Rapoport Distinguished Chair in Pediatric Endocrinology
UT Southwestern Medical Center
Dallas, TX